Why the study?
Relatively little is known about the cardiac events associated with cytokine release syndrome from CAR-T therapy that may lead to ICU admission, prolonged hospital stay, or cardiac death.
This review highlights the critical need for recognition, risk stratification, and management of cardiotoxicity associated with increasingly utilized CAR-T therapies.
Answers are grounded in this paper and cite their sources.
Supports vigilance for cardiotoxicity in CAR-T recipients; leaves open the need for prospective risk-stratification studies.
Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is being increasingly utilized, a better understanding of the unique toxicities associated with this therapy is warranted. While there is growing knowledge on the diagnosis and treatment of cytokine release syndrome (CRS), relatively little is known about the associated cardiac events that occur with CRS that may result in prolonged length of hospital stay, admission to the intensive care unit for pressor support, or cardiac death. This review focuses on the various manifestations of cardiotoxicity, potential risk factors, real world and clinical trial data on prevalence of reported cardiotoxicity events, and treatment recommendations.
No takes yet. Share an insight, caveat, or question.
Burns et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: